Literature DB >> 8183427

Effect of neurocatin on the activity of monoamine oxidase B in rat brain synaptosomes.

S Murphy1, A Pastuszko.   

Abstract

Neurocatin, a small (about 2,000 Dalton) neuroregulator isolated from mammalian brain, is a powerful effector of monoamine oxidase B in rat brain synaptosomes. Incubation of intact synaptosomes with neurocatin caused an inhibition of the enzyme dependent on the concentration of neurocatin. This inhibition became statistically significant at a neurocatin concentration of 10 ng/200 microliters and was significant at all higher neurocatin concentrations. At 40 ng/200 microliters, neurocatin inhibited monoamine oxidase B activity by about 60%. This inhibitory effect was almost completely abolished by breaking the synaptosomal membrane by hypotonic buffer prior to incubation with neurocatin. In addition, incubation of the synaptosomes in calcium free medium almost completely abolished the inhibitory effect of neurocatin on monoamine oxidase B. The inhibition appeared to involve covalent modification of the enzyme mediated by a neurocatin receptor(s). Measurements of the kinetic parameters of the enzyme showed that 20 ng of neurocatin caused a statistically significant decrease in Vmax (by 20%) with no significant change in KM, compared to controls. Inhibition of monoamine oxidase by neurocatin is potentially of great clinical importance because this enzyme plays a major role in catabolism of the biogenic amines and alterations in its activity is believed to contribute to several neurological disorders.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8183427     DOI: 10.1007/bf00966813

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  36 in total

1.  A SENSITIVE AND SPECIFIC ASSAY FOR THE ESTIMATION OF MONOAMINE OXIDASE.

Authors:  R J WURTMAN; J AXELROD
Journal:  Biochem Pharmacol       Date:  1963-12       Impact factor: 5.858

2.  Neurocatin-induced inhibition of monoamine oxidase A in rat brain synaptosomes.

Authors:  L Fernandez-Novoa; A Pastuszko; D F Wilson
Journal:  Biochem Pharmacol       Date:  1991-11-27       Impact factor: 5.858

3.  Platelet monoamine oxidase in chronic schizophrenia.

Authors:  W H Berrettini; W H Vogel; R Clouse
Journal:  Am J Psychiatry       Date:  1977-07       Impact factor: 18.112

4.  Monamine oxidase in schizophrenia and other behavioral disorders.

Authors:  D L Murphy; R Belmaker; R J Wyatt
Journal:  J Psychiatr Res       Date:  1974       Impact factor: 4.791

5.  Endogenous inhibitors of monoamine oxidase present in human cerebrospinal fluid.

Authors:  R E Becker; C Giambalvo; R A Fox; M Macho
Journal:  Science       Date:  1983-07-29       Impact factor: 47.728

6.  Mental symptoms in Huntington's disease and a possible primary aminergic neuron lesion.

Authors:  J J Mann; M Stanley; S Gershon; M Rossor
Journal:  Science       Date:  1980-12-19       Impact factor: 47.728

7.  Activation of platelet monoamine oxidase by plasma in the human.

Authors:  P H Yu; A A Boulton
Journal:  Life Sci       Date:  1979-07-02       Impact factor: 5.037

8.  Monoamine oxidase inhibitors prevent striatal neuronal necrosis induced by transient forebrain ischemia.

Authors:  Y Matsui; Y Kumagae
Journal:  Neurosci Lett       Date:  1991-05-27       Impact factor: 3.046

9.  Demonstration of endogenous inhibitors of monoamine oxidase in dog cerebrospinal fluid.

Authors:  T Egashira; R Takano; Y Yamanaka
Journal:  Jpn J Pharmacol       Date:  1986-12

10.  Elevated postmortem monoamine oxidase B activity in the caudate nucleus in Huntington's disease compared to schizophrenics and controls.

Authors:  J J Mann; R D Kaplan; E D Bird
Journal:  J Neural Transm       Date:  1986       Impact factor: 3.575

View more
  1 in total

Review 1.  90 years of monoamine oxidase: some progress and some confusion.

Authors:  Keith F Tipton
Journal:  J Neural Transm (Vienna)       Date:  2018-04-10       Impact factor: 3.575

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.